中国麻风皮肤病杂志 ›› 2026, Vol. 42 ›› Issue (11): 817-820.doi: 10.12144/zgmfskin202611817

• 综述 • 上一篇    下一篇

降钙素基因相关肽抑制剂治疗玫瑰痤疮研究进展

易黎1,孙睿2   

  1. 1海军特色医学中心，上海，200052；2上海交通大学医学院附属松江医院皮肤科，上海，201600
  • 出版日期:2026-11-15 发布日期:2026-10-29

Advances in calcitonin gene-related peptide inhibitors in the treatment of rosacea

YI Li1, SUN Rui2   

  1. 1 Naval Medical Center, Shanghai 200052, China; 2 Department of Dermatology, Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 201600, China
  • Online:2026-11-15 Published:2026-10-29

PDF (PC)

17

摘要： 玫瑰痤疮是常见的慢性炎症性皮肤病，神经免疫失衡是其发病的重要病理基础，热、辛辣食物等触发因素可激活皮肤感觉神经元，释放降钙素基因相关肽（CGRP）等神经肽。近年CGRP单克隆抗体的初步临床研究显示，该类药物初步显示可改善玫瑰痤疮患者的难治性红斑和潮红，对合并偏头痛的患者可能具有双重治疗获益。本文就CGRP参与玫瑰痤疮发病的机制及CGRP单克隆抗体的临床研究进展进行综述，旨在为玫瑰痤疮的靶向治疗提供参考。

关键词: 降钙素基因相关肽, 玫瑰痤疮, 神经源性炎症, 红斑, 潮红

Abstract: Rosacea is a common chronic inflammatory skin disease. Neuroimmune imbalance is an important pathological basis underlying the pathogenesis of rosacea. Triggers such as heat and spicy food can activate cutaneous sensory neurons and release neuropeptides including calcitonin gene-related peptide (CGRP). Preliminary clinical studies of CGRP monoclonal antibodies have shown that these agents have shown preliminary efficacy in improving refractory erythema and flushing in patients with rosacea, and may provide dual therapeutic benefits for patients with comorbid migraine. We review the role of CGRP in the pathogenesis of rosacea and the clinical research progress of CGRP monoclonal antibodies, aiming to provide a reference for the targeted treatment of rosacea.

Key words: calcitonin gene-related peptide, rosacea, neurogenic inflammation, erythema, flushing